A Phase 2 interventional study of denufosol tetrasodium Inhalation Solution and 0.9% w/v sodium chloride solution in Cystic Fibrosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 2 Years to 4 Years. Per ClinicalTrials.gov, last updated 2015-01-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cystic Fibrosis by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Cystic Fibrosis · Merck & Co., Inc.
Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, this one is the 7th largest by enrollment, is the only one that started in 2010, is one of 6 in phase 2, and was the 9th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 10 studies in Cystic Fibrosis by Merck & Co., Inc is open now. The open studies under Cystic Fibrosis, anywhere →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 2 Years to 4 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 3
First in 2001; this study’s year is marked. 1 started in 2010.
This study's enrollment of 25 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 68 across the 10 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of denufosol 60 mg TID in pediatric CF patients 2 to 4 years of age
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
rhinorrhea or nasal congestion)
Drug: denufosol tetrasodium Inhalation Solution
Drug: 0.9% w/v sodium chloride solution
60 mg by oral inhalation three times daily
0.9% w/v sodium chloride solution by oral inhalation three times daily
Intolerability to study drug as measured by: oxyhemoglobin saturation, treatment-emergent cough, and new wheezes or crackles
Time frame: Day 1, Day 7
Mean change from pre-dose in oxyhemoglobin saturation at defined times post-dose
Time frame: Day 1, Day 7
Mean change from baseline in oxyhemoglobin saturation
Time frame: Day 7
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and/or withdrawals due to TEAEs
Time frame: Day 7
Mean change from pre-dose in pulse and respiratory rate at defined times post-dose
Time frame: Day 1, Day 7
Mean change from baseline in pulse and respiratory rate
Time frame: Day 7
Incidence of new medical condition(s) or worsening of previous medical condition(s) from baseline
Time frame: Day 7
No study locations are listed for this record.
The record gives a start of Aug 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.